Archived Content

 

Day 1  |  Day 2Download Agenda 

RNAi Brochure 

Download Agenda 


RNA interference (RNAi) is being commonly used as a screening tool for identifying and validating potential drug targets, exploring unknown cellular pathways, and for performing whole-genome functional screens. The screens developed, using both small interfering RNA (siRNA) and short hairpin RNA (shRNA), are now fairly robust and sensitive and can be performed in a reliable and high-throughput fashion. The RNAi for Functional Screening conference features talks on utilizing in vitro and in vivo RNAi screens for diverse applications, choosing the right model systems and reagents, tackling RNAi delivery, off-target effects, false positives and negatives and improving quality control and data analysis.

THURSDAY, NOVEMBER 3

 

Assay Design and Set-Up 

1:30 pm Chairperson’s Remarks

Christophe Echeverri, Ph.D., CEO & CSO, Cenix BioScience GmbH

1:40 Talk Title to be Announced

Alex Gaither, Ph.D., Research Investigator II, Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research

2:10 Screening Approaches Towards Identifying Genes Associated with DNA Re-Replication in Cancer Cells

Scott Martin, Ph.D., Team Leader, RNAi Screening, NIH Chemical Genomics Center, NIH Center for Translational Therapeutics, NIH

The NIH Chemical Genomics Center has established an RNAi screening facility that performs screens in collaboration with investigators throughout the NIH intramural community. An initial genome-wide campaign involved screening for genes associated with aberrant DNA replication. Screening was conducted using libraries comprised of both pooled and individual siRNAs. Combining these approaches led to a thorough examination of genes associated with DNA replication and served as a way to compare the value of both platforms.

2:40 RNAi Screening Comes of Age: For the Love of My Target

Hakim Djaballah, Ph.D., Director, HTS Core Facility, Memorial Sloan Kettering Cancer Center

RNAi screening has offered the premise of performing several thousand simultaneous knockdowns leading to the discovery and validation of existing and novel targets. Several years on, has the technology matured enough to keep up with its premise?

3:10 Networking Refreshment Break in the Exhibit Hall with Poster Viewing

3:45 A Targeted Screen for Small Molecule Inhibitors of the Wnt/beta-catenin Pathway

Ramanuj DasGupta, Ph.D., Assistant Professor of Pharmacology and Director, RNAi Screening Facility, New York University School of Medicine/Cancer Institute


Sponsored by
Sigma_NEW 
4:15 A Library for microRNA Target Identification by Drug Selection
Kevin P. Forbes, Ph.D., Senior R&D Scientist, Sigma-Aldrich Corporation
To assist discovery and identification of human microRNA (miRNA) targets, we developed the MISSION® Target ID Library, a library of cDNA cloned after a dual-selection fusion protein. Dual-selection allows the user to transfect cells and screen the entire library at once, selecting first for stable transformants and secondly, downstream from introducing a miRNA of interest, for cDNAs containing the miRNA’s targets. Cells containing cDNA constructs targeted by the miRNA survive the second selection, and selected cDNAs can be identified by sequencing. The cDNA library was prepared from a mixture of total RNAs from multiple human tissues and cell lines to give broad coverage of the human transcriptome. Here we present preparation of the library and its use to identify targets of miR-373.

 

4:45 KEYNOTE PANEL: Has RNAi Screening Delivered On Its Promise?

Moderator: Christophe Echeverri, Ph.D., CEO/CSO, Cenix BioScience GmbH
Panelists: Hakim Djaballah, Ph.D., Director, HTS Core Facility, Memorial Sloan Kettering Cancer Center
Caroline Shamu, Ph.D., Director, ICCB-Longwood Screening Facility, Harvard Medical School
Alex Gaither, Ph.D., Research Investigator II, Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research
Scott Martin, Ph.D., Team Leader, RNAi Screening, NIH Chemical Genomics Center, NIH Center for Translational Therapeutics, NIH

Clive Geoffrey Jackson, Ph.D., Director, Biotech Evaluations Limited

5:45 End of Day

 

Day 1  |  Day 2Download Agenda 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 


2014 Discovery on Target Brochure  

green arrow FINAL BROCHURE 

PREMIER SPONSORS 

Cellecta 

green arrow VIEW ALL SPONSORS 

green arrow VIEW MEDIA PARTNERS 


SPONSORSHIPS & EXHIBITS 

The exhibit hall was sold out in 2013, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2014, contact:

Jon Stroup
Business Development Manager
781-972-5483
jstroup@healthtech.com 

2014 Discovery On Target CAG 

green arrow CONFERENCE-AT-A-GLANCE 


CONFERENCES


October 8 – 9

Targeting Epigenetic Readers and
Chromatin Remodelers
 

Targeting the Ubiquitin Proteasome System  

Big Data Analytics and Solutions  

GPCR-Based Drug Discovery  

RNAi for Functional Genomics Screening
– Part 1
 

Protein-Protein Interactions as Drug Targets  

Antibodies Against Membrane Protein Targets
– Part 1
 


October 9 – 10

Targeting Histone Methyltransferases and Demethylases  

Screening Drug Transporter Proteins  

Maximizing Efficiency in Discovery  

GPCR-Targeted Therapeutics  

Genome Editing for Functional Genomics
Screens – Part 2
 

Cancer Metabolism  

Antibodies Against Membrane Protein Targets
– Part 2
 


SYMPOSIUM


October 7

Next Generation Histone Deacetylase Inhibitors  


SHORT COURSES


October 7

SC1: Designing Scalable Software Systems for Big Data Analytics  

SC2: Approaches for Biologically-Relevant Chemical Diversity  

SC3: Setting Up Effective RNAi Screens: From Design to Data to Validation  

SC4: Targeting Protein-Protein Interactions  

SC5: GPCR Structure-Based Drug Discovery  

SC6: Advances in Metagenomic Drug Discovery for New Anti-Infective Agents  

SC7: Targeting of GPCRs with Monoclonal Antibodies  

SC8: A Primer to Gene Editing: Tools and Applications  

SC9: Introduction to Targeted Covalent Inhibitors  


October 9

SC10: Setting Up Effective Functional Screens Using 3D Cell Cultures  

SC11: Integration of BDDCS and Extended Clearance Principles  

SC12: Introduction to Allosteric Modulators and Biased Ligands of GPCRs  

SC13: Introduction to Drug Metabolism